Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
http://www.priceseries.com/trade/SLNO-Soleno-Therapeutics-Inc-stock-gains-40-percent-a-Trade-Record-by-priceSeries-2021020120210222.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments